Dr. Patel on the FDA Approval of Durvalumab in NSCLC
In Partnership With:
Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non
Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non—small cell lung cancer (NSCLC).
Related Videos
Related Content
